Diagnosis and treatment of invasive fungal infections in the cancer patient: Recent progress and ongoing questions

Clinical Infectious Diseases

Volumn 59, Issue , 2014, Pages S356-S359

  Kontoyiannis, Dimitrios P ^a,b   Patterson, Thomas F ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Aspergillosis; Cancer; Candidiasis; Diagnosis; Treatment

Indexed keywords

ANIDULAFUNGIN; ISAVUCONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT;

ANTIFUNGAL THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; HUMAN; PRIORITY JOURNAL; SYSTEMIC MYCOSIS; ASPERGILLOSIS; CANDIDIASIS; COMPLICATION; MYCOSES; NEOPLASM;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; HUMANS; MYCOSES; NEOPLASMS;

EID: 84986250599     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu591     Document Type: Article

References (37)

1. Patterson TF. Clinical utility and development of biomarkers in invasive aspergillosis. Trans Am Clin Climatol Assoc 2010; 122:174-83.
2. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004; 4:349-57.
3. Reinwald M, Hummel M, Kovalevskaya E, et al. Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies. J Antimicrob Chemother 2012; 67:2260-7.
4. Fisher CE, Stevens AM, Leisenring W, Pergam SA, Boeckh M, Hohl TM. The serum galactomannan index predicts mortality in hematopoietic stem cell transplant recipients with invasive aspergillosis. Clin Infect Dis 2013; 57:1001-4.
5. Wiederhold NP, Najvar LK, Bocanegra R, Kirkpatrick WR, Patterson TF, Thornton CR. Interlaboratory and interstudy reproducibility of a novel lateral-flow device and influence of antifungal therapy on detection of invasive pulmonary aspergillosis. J Clin Microbiol 2013; 51:459-65.
6. Sampsonas F, Kontoyiannis DP, Dickey BF, Evans SE. Performance of a standardized bronchoalveolar lavage protocol in a comprehensive cancer center: a prospective 2-year study. Cancer 2011; 117:3424-33.
7. Nucci M, Carlesse F, Cappellano P, et al. Earlier diagnosis of invasive fusariosis with Aspergillus serum galactomannan testing. PLoS One 2014; 9:e87784.
8. Nguyen MH, Wissel MC, Shields RK, et al. Performance of Candida real-time polymerase chain reaction, beta-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis 2012; 54:1240-8.
9. Ben-Ami R, Weinberger M, Orni-Wasserlauff R, et al. Time to blood culture positivity as a marker for catheter-related candidemia. J Clin Microbiol 2008; 46:2222-6.
10. Maertens J, Buve K, Theunissen K, et al. Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer 2009; 115:355-62.
11. Koo S, Baden LR, Marty FM. Post-diagnostic kinetics of the (1?3)-beta-D-glucan assay in invasive aspergillosis, invasive candidiasis and Pneumocystis jirovecii pneumonia. Clin Microbiol Infect 2012; 18: E122-7.
12. White PL, Bretagne S, Klingspor L, et al. Aspergillus PCR: one step closer to standardization. J Clin Microbiol 2010; 48:1231-40.
13. Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis 2012; 54(suppl 1):S55-60.
14. Millon L, Larosa F, Lepiller Q, et al. Quantitative polymerase chain reaction detection of circulating DNA in serum for early diagnosis of mucormycosis in immunocompromised patients. Clin Infect Dis 2013; 56: e95-101.
15. Buitrago MJ, Aguado JM, Ballen A, et al. Efficacy of DNA amplification in tissue biopsy samples to improve the detection of invasive fungal disease. Clin Microbiol Infect 2013; 19:E271-7.
16. Shah AA, Hazen KC. Diagnostic accuracy of histopathologic and cytopathologic examination of Aspergillus species. Am J Clin Pathol 2013; 139:55-61.
17. Romanelli AM, Sutton DA, Thompson EH, Rinaldi MG, Wickes BL. Sequence-based identification of filamentous basidiomycetous fungi from clinical specimens: a cautionary note. J Clin Microbiol 2010; 48:741-52.
18. Koo STH, Rearden P, Comolli J, Baden LR, Marty FM. An Aspergillus fumigatus (AF)-specific breath volatile organic compound (VOC) profile is diagnostic of invasive aspergillosis (IA). In: 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Denver, CO).
19. Neely LA, Audeh M, Phung NA, et al. T2 magnetic resonance enables nanoparticle-mediated rapid detection of candidemia in whole blood. Sci Transl Med 2013; 5:182ra54, 1-8.
20. Ranque S, Normand AC, Cassagne C, et al. MALDI-TOF mass spectrometry identification of filamentous fungi in the clinical laboratory. Mycoses 2014; 57:135-40.
21. Stanzani M, Battista G, Sassi C, et al. Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies. Clin Infect Dis 2012; 54:610-6.
22. Chamilos G, Macapinlac HA, Kontoyiannis DP. The use of 18Ffluorodeoxyglucose positron emission tomography for the diagnosis and management of invasive mould infections. Med Mycol 2008; 46:23-9.
23. Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis 2011; 52:1144-55.
24. Sipsas NV, Lewis RE, Raad II, Kontoyiannis DP. Monotherapy with caspofungin for candidaemia in adult patients with cancer: a retrospective, single institution study. Int J Antimicrob Agents 2009; 34:95-8.
25. Even C, Bastuji-Garin S, Hicheri Y, et al. Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control study. Haematologica 2011; 96:337-41.
26. Marr KA, Schlamm H, Rottinghaus ST, et al. A randomised, doubleblind study of combination therapy with voriconazole and anidulafungin versus voriconazole monotherapy for pirmary treatment of invasive aspergillosis (abstract LB 2812). In: 22nd European Congress of Clinical Microbiology and Infectious Diseases (London, UK, 31 March-4 April 2012). Basal, Switzerland: European Society of Clinical Microbiology and Infectious Diseases.
27. Thompson GR III, Wiederhold NP. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia 2010; 170:291-313.
28. Maertens J, Patterson T, Rahav G, et al. A phase 3 randomized, doubleblind trial evaluating isavuconazole vs. voriconazole for the primary treatment of invasvie fungal disease caused by Aspergillus spp. or other filamentous fungi. In: 24th European Congress of Clinical Microbiology and Infectious Diseases (Barcelona, Spain).
29. Wermers RA, Cooper K, Razonable RR, et al. Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. Clin Infect Dis 2011; 52:604-11.
30. Baxter CG, Marshall A, Roberts M, Felton TW, Denning DW. Peripheral neuropathy in patients on long-term triazole antifungal therapy. J Antimicrob Chemother 2011; 66:2136-9.
31. Zwald FO, Spratt M, Lemos BD, et al. Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation. Dermatol Surg 2012; 38:1369-74.
32. Marr KA, LeisenringW, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103:1557-9.
33. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327-60.
34. Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47: 674-83.
35. Lewis RE, Cahyame-Zuniga L, Leventakos K, et al. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. Mycoses 2013; 56:638-45.
36. Patterson TF. Risk stratification for invasive aspergillosis: early assessment of host susceptibility. Med Mycol 2009; 47(suppl 1):S255-60.
37. Stanzani M, Lewis RE, Fiacchini M, et al. A risk prediction score for invasive mold disease in patients with hematological malignancies. PLoS One 2013; 8:e75531.